Is Imfinzi Effective for Biliary Tract Cancer? (TOPAZ-1 Trial)
Medical Supporter — Avis d’information
Cet article est une synthèse d’informations médicales internationales et ne constitue pas un avis médical ; il ne remplace pas le diagnostic ni le plan de traitement de votre médecin traitant. Les informations présentées sont compilées à partir de publications publiques et de déclarations officielles d’établissements médicaux japonais ; l’adéquation et les résultats de toute thérapie varient selon chaque patient et doivent être évalués individuellement par un médecin qualifié.
On January 18, 2022, AstraZeneca announced the results of the TOPAZ-1 Phase 3 clinical trial. The study evaluated the efficacy and safety of Imfinzi (durvalumab), an anti-PD-L1 antibody, in combination with standard chemotherapy as a first-line treatment for patients with unresectable advanced or metastatic biliary tract cancer (BTC).
Study Design: TOPAZ-1 Phase 3 Trial
TOPAZ-1 is an international, multi-center, double-blind, randomized Phase 3 trial. It included 685 patients with unresectable advanced or metastatic BTC (including intrahepatic and extrahepatic cholangiocarcinoma and gallbladder cancer). Patients were randomized into two groups:
- Imfinzi Group: Imfinzi + Standard Chemotherapy (Gemcitabine and Cisplatin) (N=341)
- Placebo Group: Placebo + Standard Chemotherapy (N=344)
The primary endpoint was overall survival (OS). Secondary endpoints included progression-free survival (PFS), objective response rate (ORR), and safety.
Key Survival Results
Overall Survival (OS)
- Median OS: 12.8 months for the Imfinzi group vs. 11.5 months for the placebo group.
- The Imfinzi combination reduced the risk of death by 20% (Hazard Ratio [HR] = 0.80).
- 18-Month OS Rate: 35.1% (Imfinzi) vs. 25.6% (Placebo).
- 24-Month OS Rate: 24.9% (Imfinzi) vs. 10.4% (Placebo).
Progression-Free Survival (PFS)
- Median PFS: 7.2 months (Imfinzi) vs. 5.7 months (Placebo).
- The risk of disease progression or death was reduced by 20% in the Imfinzi group.
Objective Response Rate (ORR)
- ORR: 26.7% for the Imfinzi group vs. 18.7% for the placebo group.
Safety Profile
The incidence of Grade 3 or 4 adverse events was similar between the two groups: 62.7% in the Imfinzi group and 64.9% in the placebo group. Discontinuation of treatment due to adverse events occurred in 8.9% of patients in the Imfinzi group and 11.4% in the placebo group.
Conclusion
Dr. Do-Youn Oh from Seoul National University Hospital noted that there had been no significant progress in treating advanced biliary tract cancer for over a decade. The TOPAZ-1 trial demonstrates that Imfinzi plus chemotherapy significantly improves overall survival with a favorable safety profile, establishing this combination as a potential new standard of care for advanced BTC.
Source: AstraZeneca Press Release - TOPAZ-1 Results
#BiliaryTractCancer #Cholangiocarcinoma #Imfinzi #Durvalumab #TOPAZ1 #CancerResearch
Vous envisagez des soins au Japon ? Besoin d’informations et d’aide ?
Nous vous aidons à rassembler les informations nécessaires pour un déplacement médical au Japon, à contacter les établissements japonais et à organiser une consultation de second avis.La première consultation est gratuite ; un conseiller vous aide à clarifier les prochaines étapes.
Figure 1